Urology
Volume 68, Issue 3, Supplement , Pages 47-60 , September 2006

Cardiovascular safety of sildenafil citrate (Viagra®): An updated perspective

  • Graham Jackson

      Affiliations

    • St. Thomas Hospital, London, United Kingdom
    • Graham Jackson and Melvin D. Cheitlin are consultants to, and meeting participants and lecturers for, Pfizer Inc.
    • Corresponding Author InformationReprint requests: Graham Jackson, MD, FESC, FRCP, FACC, Cardiology Department, St. Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom.
    • ,
  • Piero Montorsi

      Affiliations

    • Institute of Cardiology, University of Milan Centro Cardiologico, Milan, Italy
    • ,
  • Melvin D. Cheitlin

      Affiliations

    • San Francisco General Hospital, San Francisco, California, USA.
    • Graham Jackson and Melvin D. Cheitlin are consultants to, and meeting participants and lecturers for, Pfizer Inc.

References 

  1. Data on file . New York, NY: Pfizer Inc; 2005;
  2. Padma-Nathan H , Eardley I , Kloner RA , et al.   A 4-year update on the safety of sildenafil citrate (Viagra®) . Urology . 2002;60(suppl 2B):67–90
  3. Cheitlin MD , Hutter AM , Brindis RG , et al.   American College of Cardiology/American Heart Association Writing Group: ACC/AHA expert consensus document: use of sildenafil (Viagra) in patients with cardiovascular disease . J Am Coll Cardiol . 1999;33:273–282
  4. DeBusk R , Drory Y , Goldstein I , et al.   Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel . Am J Cardiol . 2000;86:175–181
  5. Jackson G , Betteridge J , Dean J , et al.   A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement . Int J Clin Pract . 1999;53:445–451
  6. Jackson G , Betteridge J , Dean J , et al.   A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement—update 2002 . Int J Clin Pract . 2002;56:663–671
  7. Kostis JB , Jackson G , Rosen R , et al.   Sexual dysfunction and cardiac risk: the 2nd Princeton Consensus Conference . Am J Cardiology . 2005;96:313–321
  8. Katzenstein L , Grossman EB . Viagra (Sildenafil Citrate): The Remarkable Story of the Discovery and Launch . New York: Medical Information Press; 2001;
  9. Osterloh I , Phillips S . Sildenafil and the NO/cGMP signaling pathway . In:  Kloner R editors. Heart Disease and Erectile Dysfunction . Totowa, NJ: Humana Press; 2004;p. 89–116
  10. Ballard SA , Gingell CJ , Tang K , et al.   Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes . J Urol . 1998;159:2164–2171
  11. Jeremy JY , Ballard SA , Naylor AM , et al.   Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro . Br J Urol . 1997;79:958–963
  12. Pfeifer A , Ruth P , Dostmann W , et al.   Structure and function of cGMP-dependent protein kinases . Rev Physiol Biochem Pharmacol . 1999;135:105–149
  13. Kwan H-Y , Huang Y , Xiaoqiang Y . Store-operated calcium entry in vascular endothelial cells is inhibited by cGMP via a protein kinase G-dependent mechanism . J Biol Chem . 2000;275:6758–6763
  14. Surks HK , Mochizuki N , Kasai Y , et al.   Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha . Science . 1999;286:1583–1587
  15. Verma S , Anderson TJ . Fundamentals of endothelial function for the clinical cardiologist . Circulation . 2002;105:546–549
  16. Feldman HA , Goldstein I , Hatzichristou DG , et al.   Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study . J Urol . 1994;151:54–61
  17. Dishy V , Sofowora G , Harris PA , et al.   The effect of sildenafil on nitric oxide–mediated vasodilation in healthy men . Clin Pharmacol Ther . 2001;70:270–279
  18. Jackson G , Benjamin N , Jackson N , et al.   Effects of sildenafil citrate on human hemodynamics . Am J Cardiol . 1999;83:13C–20C
  19. Zusman RM , Morales A , Glasser DB , et al.   Overall cardiovascular profile of sildenafil citrate . Am J Cardiol . 1999;83:35C–44C
  20. Zusman RM , Prisant LM , Brown MJ  Sildenafil Study Group . Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication . J Hypertens . 2000;18:1865–1869
  21. Pickering TG , Shepherd AM , Puddey IB , et al.   Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial . Am J Hypertens . 2004;17:1135–1142
  22. Webb DJ , Freestone S , Allen MJ , et al.   Sildenafil citrate and blood-pressure–lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist . Am J Cardiol . 1999;83:21C–28C
  23. Vardi Y , Klein L , Nassar S , et al.   Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men . Urology . 2002;59:747–752
  24. Arruda-Olson AM , Mahoney DW , Nehra A , et al.   Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial . JAMA . 2002;287:719–725
  25. Manfroi WC , Caramori PR , Zago AJ , et al.   Hemodynamic effects of sildenafil in patients with stable ischemic heart disease . Int J Cardiol . 2003;90:153–157
  26. Herrmann HC , Chang G , Klugherz BD , et al.   Hemodynamic effects of sildenafil in men with severe coronary artery disease . N Engl J Med . 2000;342:1622–1626
  27. Vardi Y , Bulus M , Reisner S , et al.   Effects of sildenafil citrate (Viagra®) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease . Eur Urol . 2003;43:544–551
  28. Corbin J , Rannels S , Neal D , et al.   Sildenafil citrate does not affect cardiac contractility in human or dog heart . Curr Med Res Opin . 2003;19:747–752
  29. Jackson G , Keltai M , Csanady M , et al.   Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction . J Sex Med . 2005;2:407–414
  30. Halcox JPJ , Nour KRA , Zalos G , et al.   The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia . J Am Coll Cardiol . 2002;40:1232–1240
  31. Fox KM , Thadani U , Ma PTS , et al.   on behalf of the CAESAR I (Clinical American and European Studies of Angina and Revascularization) investigators: Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina . Eur Heart J . 2003;24:2206–2212
  32. Patrizi R , Leonardo F , Pelliccia F , et al.   Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers . Ital Heart J . 2001;2:841–844
  33. Dustan Sarazan R , Crumb WJ , Beasley CM , et al.   Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5—sildenafil, tadalafil, and vardenafil . Eur J Pharmacol . 2004;502:163–167
  34. Alpaslan M , Onrat E , Samli M , et al.   Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety . Ann Noninvasive Electrocardiol . 2003;8:14–17
  35. Kaya D , Guler C , Esen AM , et al.   Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis . Ann Noninvasive Electrocardiol . 2004;9:228–233
  36. Morganroth J , Ilson BE , Shaddinger BC , et al.   Evaluation of vardenafil and sildenafil on cardiac repolarization . Am J Cardiol . 2004;93:1378–1383
  37. Morales A , Gingell C , Collins M , et al.   Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction . Int J Impot Res . 1998;10:69–74
  38. Conti CR , Pepine CJ , Sweeney M . Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease . Am J Cardiol . 1999;83:29C–34C
  39. Kloner RA , Brown M , Prisant LM , et al.   Sildenafil Study Group: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy . Am J Hypertens . 2001;14:70–73
  40. Mittleman MA , Glasser DB , Orazem J . Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo . Int J Clin Pract . 2003;57:597–600
  41. Mittleman MA , Maclure M , Glasser DB . Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate . Am J Cardiol . 2005;96:443–446
  42. Boshier A , Wilton LV , Shakir SA . Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999 . BJU Int . 2004;93:796–801
  43. Shakir SAW , Wilton LV , Boshier A , et al.   Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England . BMJ . 2001;322:651–652
  44. Giuliano F , Porst H , Hedelin H , et al.   Cardiovascular safety of Viagra® (sildenafil citrate): results of the international men’s health study . [Abstract] Eur Urol . 2005;4(suppl 3):137
  45. Israilov S , Baniel J , Shmueli J , et al.   Treatment program for erectile dysfunction in patients with cardiovascular diseases . Am J Cardiol . 2004;93:689–693
  46. DeBusk RF , Pepine CJ , Glasser DB , et al.   Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease . Am J Cardiol . 2004;93:147–153
  47. Aranda P , Ruilope LM , Calvo C , et al.   Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study . Am J Hypertens . 2004;17:139–145
  48. Rosen RC , Cappelleri JC , Smith MD , et al.   Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction . Int J Impot Res . 1999;11:319–326
  49. Olsson AM , Persson CA . Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease . Int J Clin Pract . 2001;55:171–176
  50. Viagra® (sildenafil citrate) [full prescribing information] . New York, NY: Pfizer Inc; 2005;
  51. Muller JE . Sexual activity as a trigger for cardiovascular events: what is the risk? . Am J Cardiol . 1999;84:2N–5N
  52. Webb DJ , Muirhead GJ , Wulff M , et al.   Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina . J Am Coll Cardiol . 2000;36:25–31

PII: S0090-4295(06)00891-0

doi: 10.1016/j.urology.2006.05.047

Urology
Volume 68, Issue 3, Supplement , Pages 47-60 , September 2006

Article Tools

* Image Usage & Resolution